# Factor XIII Supplementation in Postpartum Hemorrhage: From Biological Rationale to Clinical Implementation

## TL;DR

This paper explores using factor XIII to treat postpartum hemorrhage, a leading cause of maternal death, by examining its biological role and clinical potential.

## Contribution

The paper introduces the first randomized trial of FXIII supplementation for PPH and discusses its biological rationale.

## Key findings

- FXIII activity decreases during pregnancy and further during PPH.
- Low FXIII levels predict increased bleeding risk, and supplementation improves clot firmness in lab tests.
- The SWIFT trial is the first to evaluate FXIII supplementation in PPH patients.

## Abstract

Postpartum hemorrhage (PPH) remains the leading cause of preventable maternal mortality despite standard interventions. Recent fibrinogen trials failed to improve outcomes, prompting interest in coagulation factor XIII (FXIII). FXIII functions as “molecular cement,” cross‐linking fibrin and stabilizing clots. During pregnancy, FXIII activity decreases 20%–30%, with further depletion during PPH. Observational studies show low antepartum FXIII predicts bleeding risk, while ex vivo supplementation restores clot firmness. The SWIFT trial (NCT06481995) represents the first randomized controlled trial evaluating early FXIII supplementation in PPH. Although implementation challenges are significant (diagnostic accessibility, thrombotic monitoring, supply constraints), even modest hemostatic improvements could substantially reduce maternal mortality.